Reminder - Sabine Royalty Trust (SBR) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 6/11/15, Sabine Royalty Trust (SBR) will trade ex-dividend, for its monthly dividend of $0.2187, payable on 6/29/15. As a percentage of SBR's recent stock price of $39.73, this dividend works out to approximately 0.55%, so look for shares of Sabine Royalty Trust to trade 0.55% lower — all else being equal — when SBR shares open for trading on 6/11/15.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for SBR, showing historical dividends prior to the most recent $0.2187 declared by Sabine Royalty Trust:

SBR+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from SBR is likely to continue, and whether the current estimated yield of 6.61% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of SBR shares, versus its 200 day moving average:

Sabine Royalty Trust 200 Day Moving Average Chart

Looking at the chart above, SBR's low point in its 52 week range is $33.77 per share, with $63.91 as the 52 week high point — that compares with a last trade of $39.73.

In Tuesday trading, Sabine Royalty Trust shares are currently up about 0.8% on the day.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says